AU604672B2 - Long acting formulation - Google Patents

Long acting formulation Download PDF

Info

Publication number
AU604672B2
AU604672B2 AU68102/87A AU6810287A AU604672B2 AU 604672 B2 AU604672 B2 AU 604672B2 AU 68102/87 A AU68102/87 A AU 68102/87A AU 6810287 A AU6810287 A AU 6810287A AU 604672 B2 AU604672 B2 AU 604672B2
Authority
AU
Australia
Prior art keywords
calcium channel
alkyl
pharmaceutical composition
channel blocker
spheroids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU68102/87A
Other languages
English (en)
Other versions
AU6810287A (en
Inventor
Michael J. Dey
Calum B. Macfarlane
Alastair B. Selkirk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syntex USA LLC
Original Assignee
Syntex USA LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex USA LLC filed Critical Syntex USA LLC
Publication of AU6810287A publication Critical patent/AU6810287A/en
Application granted granted Critical
Publication of AU604672B2 publication Critical patent/AU604672B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/82—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU68102/87A 1986-01-30 1987-01-29 Long acting formulation Expired AU604672B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US82389686A 1986-01-30 1986-01-30
US823896 1986-01-30
US94087886A 1986-12-10 1986-12-10
US940878 1986-12-10

Publications (2)

Publication Number Publication Date
AU6810287A AU6810287A (en) 1987-08-06
AU604672B2 true AU604672B2 (en) 1991-01-03

Family

ID=27124769

Family Applications (1)

Application Number Title Priority Date Filing Date
AU68102/87A Expired AU604672B2 (en) 1986-01-30 1987-01-29 Long acting formulation

Country Status (18)

Country Link
EP (1) EP0231026B1 (enExample)
JP (1) JP2524990B2 (enExample)
KR (1) KR900005009B1 (enExample)
AU (1) AU604672B2 (enExample)
CA (1) CA1285227C (enExample)
DE (1) DE3782439T2 (enExample)
DK (1) DK175216B1 (enExample)
ES (1) ES2052500T3 (enExample)
FI (1) FI88872C (enExample)
GR (1) GR3006148T3 (enExample)
HU (1) HU196709B (enExample)
IE (1) IE61879B1 (enExample)
IL (2) IL81419A0 (enExample)
IT (1) IT1206876B (enExample)
NO (1) NO174325C (enExample)
NZ (1) NZ219090A (enExample)
PH (1) PH26366A (enExample)
PT (1) PT84213B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4940556A (en) * 1986-01-30 1990-07-10 Syntex (U.S.A.) Inc. Method of preparing long acting formulation
IE63321B1 (en) * 1986-02-03 1995-04-05 Elan Corp Plc Drug delivery system
DE3830749A1 (de) * 1987-09-11 1989-03-30 Squibb & Sons Inc Arzneimittel in form von kuegelchen mit hohem arzneistoffgehalt und verfahren zu ihrer herstellung
JP2528706B2 (ja) * 1988-05-30 1996-08-28 ゼリア新薬工業株式会社 ジヒドロピリジン化合物の製剤組成物
US4925676A (en) * 1989-02-02 1990-05-15 Warner-Lambert Company Extended release gemfibrozil composition
HU203041B (en) * 1989-03-14 1991-05-28 Egyt Gyogyszervegyeszeti Gyar Process for producing pharmaceutical compositions of controlled releasing factor containing nifedipin
JPH0729926B2 (ja) * 1989-07-25 1995-04-05 大塚製薬株式会社 易吸収性製剤用組成物
ES2150438T3 (es) * 1991-12-30 2000-12-01 Fmc Corp Composicion de esferonizacion a base de celulosa microcristalina.
DE69311394T2 (de) * 1992-02-20 1997-10-30 Euro Celtique Sa Arzneimittel verzögerter Wirkstoffabgabe
GB9203689D0 (en) * 1992-02-20 1992-04-08 Euro Celtique Sa Pharmaceutical composition
TW474824B (en) * 1996-09-13 2002-02-01 Basf Ag The production of solid pharmaceutical forms
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
EP1027885B1 (en) * 1999-02-09 2008-07-09 Pfizer Products Inc. Basic drug compositions with enhanced bioavailability
AU2005320547B2 (en) 2004-12-27 2009-02-05 Eisai R & D Management Co., Ltd. Method for stabilizing anti-dementia drug
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795766A (fr) * 1972-02-22 1973-08-22 Lilly Co Eli Particules de napsylate de propoxyphene retard et procede de fabrication de ces particules
JPS5846019A (ja) * 1981-09-14 1983-03-17 Kanebo Ltd 持続性ニフエジピン製剤
FR2581541B1 (fr) * 1985-05-09 1988-05-20 Rhone Poulenc Sante Nouvelles compositions pharmaceutiques permettant la liberation prolongee d'un principe actif et leur procede de preparation

Also Published As

Publication number Publication date
IL81419A0 (en) 1987-08-31
NO870368L (no) 1987-07-31
PT84213B (pt) 1989-03-30
FI88872B (fi) 1993-04-15
IE870229L (en) 1987-07-30
DK47787D0 (da) 1987-01-29
NZ219090A (en) 1990-04-26
IE61879B1 (en) 1994-11-30
GR3006148T3 (enExample) 1993-06-21
ES2052500T3 (es) 1994-07-16
AU6810287A (en) 1987-08-06
IL81419A (en) 1991-07-18
DK175216B1 (da) 2004-07-12
FI870380L (fi) 1987-07-31
NO870368D0 (no) 1987-01-29
EP0231026A1 (en) 1987-08-05
FI870380A0 (fi) 1987-01-29
IT1206876B (it) 1989-05-11
JPS62252732A (ja) 1987-11-04
KR870007121A (ko) 1987-08-17
JP2524990B2 (ja) 1996-08-14
PT84213A (en) 1987-02-01
IT8767057A0 (it) 1987-01-29
HUT42950A (en) 1987-09-28
CA1285227C (en) 1991-06-25
FI88872C (fi) 1993-07-26
NO174325B (no) 1994-01-10
DE3782439D1 (de) 1992-12-10
EP0231026B1 (en) 1992-11-04
HU196709B (en) 1989-01-30
PH26366A (en) 1992-06-01
DK47787A (da) 1987-07-31
DE3782439T2 (de) 1993-05-19
NO174325C (no) 1994-04-20
KR900005009B1 (ko) 1990-07-16

Similar Documents

Publication Publication Date Title
US5198226A (en) Long acting nicardipine hydrochloride formulation
US4940556A (en) Method of preparing long acting formulation
US5209933A (en) Long acting calcium channel blocker composition
AU604672B2 (en) Long acting formulation
US5470584A (en) Diltiazem formulation
CA2396380C (en) Improved pharmaceutical compositions for poorly soluble drugs
JP2637981B2 (ja) 吸収制御薬剤組成物
CA2124012C (fr) Formulation de diltiazem a liberation prolongee
CA1312286C (en) Pharmaceutical preparation containing metoprolol
US4917899A (en) Controlled absorption diltiazem formulation
EP0149920A2 (en) Pharmaceutical formulation
PT1689370E (pt) Método para a preparação de uma composição farmacêutica sólida para administração oral
HU197839B (en) Process for producing metoprolol containing pharmaceutical compositions
EP0514814B1 (en) Diltiazem formulation
BR112013003158B1 (pt) composições farmacêuticas de antagonistas do receptor glutamato metabotrópico 5 (mglu5)
JP4296562B2 (ja) 硫酸モルヒネ微小顆粒、その調製方法およびそれを含有する組成物
PT1178780E (pt) Formulações de inibidores selectivos da reassimilação de serotonina, de libertação controlada e multiparticularidades
PT2001445E (pt) Esferoides farmacêuticos
JPH10120571A (ja) 塩酸ジルチアゼム徐放性製剤
WO2019199246A1 (en) A sustained release formulation comprising acemetacin with bimodal in vitro release
IE60929B1 (en) Controlled absorption diltiazem formulation
JP2707023C (enExample)